A Consecutive and Prospective Stroke Database Covers the State of Baden-Wuerttemberg with 10.8 Million Inhabitants in Germany

Gumbinger, Christoph; Reuter, Björn; Wiethölter, H.; Bruder, Ingo; Rode, Susanne; Drewitz, Elke; Habscheid, W.; Daffertshofer, Michael; Diehm, Curt; Neumaier, Stephan; Kern, Rolf; Ringleb, Peter A.; Hacke, Werner; Hennerici, Michael G.

doi:10.1159/000354356

Cited by 22 publications

(31 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The primary efficacy end point was disability at 90 days or the last rating as assessed on the mRS, dichotomized as a success (score, 0-2) or a failure (score, [3][4][5][6]. The primary efficacy end point was intended to be evaluated with hierarchical Bayesian analysis incorporating relevant previous data from the NEST 2.…”

Section: Methodsmentioning

confidence: 99%

“…[1][2][3][4] The holy grail of neuroprotection has been sought through a range of pharmacological approaches, none with sustained success. 5,6 In a nonpharmacological approach in which near-infrared laser energy was delivered transcranially has been hypothesized to modulate biochemical changes within neural cells and to be a candidate neuroprotective approach.…”

Section: See Related Article P 3175mentioning

confidence: 99%

See 1 more Smart Citation

Transcranial Laser Therapy in Acute Stroke Treatment

Hacke¹,

Schellinger²,

Albers³

et al. 2014

Stroke

View full text Add to dashboard Cite

Background and Purpose-On the basis of phase II trials, we considered that transcranial laser therapy could have neuroprotective effects in patients with acute ischemic stroke. Methods-We studied transcranial laser therapy in a double-blind, sham-controlled randomized clinical trial intended to enroll 1000 patients with acute ischemic stroke treated ≤24 hours after stroke onset and who did not undergo thrombolytic therapy. The primary efficacy measure was the 90-day functional outcome as assessed by the modified Rankin Scale, with hierarchical Bayesian analysis incorporating relevant previous data. Interim analyses were planned after 300 and 600 patients included. Results-The study was terminated on recommendation by the Data Monitoring Committee after a futility analysis of 566 completed patients found no difference in the primary end point (transcranial laser therapy 140/282 [49.6%] versus sham 140/284 [49.3%] for good functional outcome; modified Rankin Scale, 0-2). The results remained stable after inclusion of all 630 randomized patients (adjusted odds ratio, 1.024; 95% confidence interval, 0.705-1.488). Conclusions-Once the results of the interim futility analysis became available, all study support was immediately withdrawn by the capital firms behind PhotoThera, and the company was dissolved. Proper termination of the trial was difficult but was finally achieved through special efforts by former employees of PhotoThera, the CRO Parexel and members of the steering and the safety committees. We conclude that transcranial laser therapy does not have a measurable neuroprotective effect in patients with acute ischemic stroke when applied within 24 hours after stroke onset. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01120301. This series of basic science studies preceded 2 randomized phase IIa and IIb clinical trials, the neurothera effectiveness and safety trials (NEST)-1 and NEST 2, which included 780 patients (120 in NEST 1 and 660 in NEST 2).12,13 These provided reassuring safety data in patients, but the larger trial was neutral on efficacy end points. However, the combined data were interpreted as showing positive trends that justified definitive testing.14 From the second of these trials, a post hoc analysis identified a subgroup that was hypothesized to have higher potential for efficacy and this formed the target population for the present clinical trial. 13 We conducted a randomized trial to test for the benefit of TLT in improving the proportion of patients with good functional outcome (modified Rankin Scale [mRS], 0-2) at 90 days after stroke onset. Methods Study DesignNEST 3 was a double-blind, randomized, sham-controlled, parallel group, multicenter trial intended to enroll ≤1000 patients from ≈150 investigational sites. Patients were eligible for inclusion if they were aged 40 to 80 years, had a clinical diagnosis of acute ischemic stroke, no evidence of hemorrhagic infarct exceeding petechial bleeding along the margins, had a baseline National Instit...

show abstract

Section: Methodsmentioning

confidence: 99%

Section: See Related Article P 3175mentioning

confidence: 99%

Transcranial Laser Therapy in Acute Stroke Treatment

Hacke¹,

Schellinger²,

Albers³

et al. 2014

Stroke

View full text Add to dashboard Cite

show abstract

“…Details des Schlaganfallregisters wurden anderweitig publiziert [7]. Der Einschluss erfolgte anhand der ICD-10-Codes I63.0-I63.5, I63.8-I63.9, I64, I67.0 für alle Patienten, die innerhalb von 7 Tagen nach dem Einsetzen der Schlaganfallsymptome aufgenommen wurden [6,7].…”

Section: Methodikunclassified

“…Für die Versorgung von Schlaganfallpatienten in BadenWürttemberg wurde im Jahr 1998 ein Schlaganfallkonzept entwickelt, das ein dreistufiges Versorgungsmodell, basierend auf Stroke-Units (Schlaganfall-Einheiten), vorsieht. Dies beinhaltet Krankenhäuser mit lokalen und möglichst wohnortnahen Schlaganfalleinheiten, regionalen Stroke-Units in urbanen Gebieten und Schlaganfallzentren in Ballungsräumen [7]. Ein Teil der Patienten wird weiter außerhalb von Schlaganfallstationen behandelt.…”

Section: Introductionunclassified

“…Ein wesentlicher Bestandteil des baden-württembergischen Schlaganfallversorgungskonzepts ist ein seit dem Jahr 2005 bestehendes Register zur Qualitätssicherung der Schlaganfallversorgung. Für jeden Schlaganfallpatienten ist vom behandelnden Krankenhaus ein obligatorischer Datensatz an die Geschäftsstelle für Qualitätssicherung im Krankenhaus (GeQiK) in Stuttgart zu übermitteln, dies betrifft nicht nur Krankenhäuser mit Stroke-Unit, sondern alle Krankenhäuser und alle Fachabteilungen, wodurch sich die Qualitäts-sicherung von anderen Bundesländern in Deutschland positiv hervorhebt [7]. Dieser Datensatz umfasst Items mit detaillierten klinischen, diagnostischen und therapeutischen Informationen und muss von jedem Krankenhaus für jeden behandelten Schlaganfallpatienten übermittelt werden, der < 7 Tage nach Symptombeginn aufgenommen wird.…”

Section: Introductionunclassified

See 1 more Smart Citation

Möglichkeiten der Schlaganfallversorgungsforschung

Gumbinger

Ringleb

2016

Gefässchirurgie

Self Cite

View full text Add to dashboard Cite

Die systemische Thrombolysether apie im 4,5hZeitfenster ab Symptombeginn ist die ein zige zugelassene medikamentöse Akuttherapie des ischämischen Schlaganfalls. Parallel zur Einführung der Thrombolysetherapie wurden komplexe Versorgungsstrukturen mit einer flächendeckenden Einführung von StrokeUnits etabliert. Von vorne herein war festgelegt worden, dass diese Entwicklung von gesetzlich ver pflichtenden Qualitätssicherungs maßnahmen begleitet werden soll, was heute die Möglichkeit gibt, für die Versorgungsforschung relevante Fragestellungen zu bearbeiten. In diesem Beitrag werden zwei beispiel hafte Analysen vorgestellt.

show abstract